Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases

Revista clinica espanola Pub Date : 2024-08-01 DOI:10.1016/j.rceng.2024.06.001

{"title":"Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases","authors":"","doi":"10.1016/j.rceng.2024.06.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The long-term use of rituximab<span><span> (RTX) has been gaining ground in the treatment of systemic autoimmune diseases. The </span>adverse events (AEs) associated with its use different to infections are being reported.</span></p></div><div><h3>Methods</h3><p>A cohort of patients with SAIDs treated at a high-complexity center in Cali (southwestern Colombia) with follow-up from January 2008 to December 2022 were examined to search for potential AEs associated with prolonged use of RTX.</p></div><div><h3>Results</h3><p><span>From 178 patients with long-term use of RTX 3 (1.68%) had lymphadenopathies with </span>lymphoid follicular hyperplasia<span><span> related to BAFF<span> overexpression, 4 (2.24%) with bronchiectasis, and 4 (2.24%) with lymphoplasmacytic </span></span>cystitis.</span></p></div><div><h3>Conclusion</h3><p><span><span>Bronchiectasis, lymphoid follicular hyperplasia related to </span>BAFF overexpression, and lymphoplasmacytic </span>cystitis may be life-threatening long-term AEs in patients with prolonged use of RTX.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 7","pages":"Pages 474-478"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2254887424000791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The long-term use of rituximab (RTX) has been gaining ground in the treatment of systemic autoimmune diseases. The adverse events (AEs) associated with its use different to infections are being reported.

Methods

A cohort of patients with SAIDs treated at a high-complexity center in Cali (southwestern Colombia) with follow-up from January 2008 to December 2022 were examined to search for potential AEs associated with prolonged use of RTX.

Results

From 178 patients with long-term use of RTX 3 (1.68%) had lymphadenopathies with lymphoid follicular hyperplasia related to BAFF overexpression, 4 (2.24%) with bronchiectasis, and 4 (2.24%) with lymphoplasmacytic cystitis.

Conclusion

Bronchiectasis, lymphoid follicular hyperplasia related to BAFF overexpression, and lymphoplasmacytic cystitis may be life-threatening long-term AEs in patients with prolonged use of RTX.

查看原文本刊更多论文

支气管扩张、与 BAFF 过度表达相关的淋巴腺病变和淋巴浆细胞性膀胱炎是全身性自身免疫性风湿病患者长期使用利妥昔单抗的不良反应。

背景：长期使用利妥昔单抗（RTX）治疗全身性自身免疫性疾病的趋势越来越明显。与感染相关的不良事件（AEs）也有报道：方法：研究人员对2008年1月至2022年12月期间在卡利（哥伦比亚西南部）一家高复杂性中心接受治疗的SAIDs患者进行了队列研究，以寻找与长期使用RTX相关的潜在AEs：结果：在178名长期使用RTX的患者中，有3人（1.68%）患有与BAFF过度表达相关的淋巴腺病和淋巴滤泡增生，4人（2.24%）患有支气管扩张，4人（2.24%）患有淋巴浆细胞性膀胱炎：结论：支气管扩张、与BAFF过度表达相关的淋巴滤泡增生和淋巴浆细胞性膀胱炎可能是长期使用RTX患者中危及生命的长期AEs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista clinica espanola

自引率

0.00%

发文量